MCM
ADAP

MAI Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

MAI Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,534
Closed -$65K – 931
2021
Q3 		$65K Hold
12,534
– – ﹤0.01% 764
2021
Q2 		$53K Hold
12,534
– – ﹤0.01% 749
2021
Q1 		$67K Buy
12,534
+1,000
+9% +$5.72K ﹤0.01% 703
2020
Q4 		$62K Hold
11,534
– – ﹤0.01% 657
2020
Q3 		$92K Buy
+11,534
New +$101K ﹤0.01% 565

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAI Capital Management's ADAP Position: Q4 2021 in Review

MAI Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 12,534 shares — an estimated $65K sold.

MAI Capital Management first reported a position in ADAP in Q3 2020 and held it in 5 quarters. The position peaked at $92K in Q3 2020. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • MAI Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • MAI Capital Management sold 12,534 Adaptimmune Therapeutics shares in Q4 2021, an estimated $65K.
  • MAI Capital Management first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 5 quarters.
  • MAI Capital Management's Adaptimmune Therapeutics position peaked at $92K in Q3 2020.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on MAI Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.